BG Medicine said this week that is compliant with requirements for listing on the Nasdaq Capital Market.
BG requested transfer to the Capital Market in January after failing to meet the $50 million market value of listed securities requirement for listing on the Global Market. The Capital Market requires a company maintain $35 million market value or $2.5 million in stockholders equity.
As of its transfer request, the company was not compliant with the Capital Market requirements, either. However, it has since achieved compliance.
The company also noted this week that the Cardiological Society of India's 2014 Indian Consensus Document on Cardiac Biomarkers included galectin-3 as a biomarker useful in evaluating the risk of heart failure.
The document stated that "B-type natriuretic peptide, in conjunction with galectin-3, may be used to identify those patients at higher risk of readmission or death thus allowing the physician to better match the level of care to an individual patient's needs."
In a statement, BG Medicine CEO Paul Sohmer cited the inclusion of galectin-3 as "an important recognition of the potential significance of galectin-3 testing in the evaluation and management of patients with heart failure."